You are here:
Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
The primary focus of the BCRT is on diseases of the immune system, the musculoskeletal system and the cardiovascular system for which currently only unsatisfactory treatment options are available. At the BCRT clinicians and researchers are working hand in hand on the medicine of the future: targeted, personalized medicine that depends on the early recognition of patients' individual healing potential.
The BCRT was founded in 2006 as an alliance between the Charité – Universitätsmedizin Berlin, one of Europe's largest university clinics, and the Helmholtz Association, Germany's largest research association. A team of over 250 employees – including physicians, scientists, engineers, experts in translational medicine, PhD students and technical staff – are conducting research at the BCRT's two sites: at the BCRT building on the Virchow Clinic Campus of the Charité, with its close links to the BCRT partner clinics, and at the Teltow Campus of the Helmholtz Centre Geesthacht, the Centre for Biomaterial Development.
What are we working on?
- Development of methods and tools for regenerative therapies on the basis of immune cells, stem cells, biomaterials, biologically active factors and combinations of these.
- Development of biomarkers for the optimal application of these novel regenerative therapies with the aim of tailoring the therapy to suit the needs of the patient (particularly for diseases of the immune system, the musculoskeletal system and the cardiovascular system) and applying it at the respective optimal point in time.
- Rapid transfer of research findings into preclinical and clinical studies to develop new regenerative therapies.
- Targeted training of the next generation of scientists: qualified physicians, scientists and engineers who conduct both basic and applied research in the field of regenerative medicine.
- Promotion of partnerships with health insurers, regulatory authorities, health economy experts as well as with representatives and partners of the biotech and pharma industries.